Bill Brown (Chairman) and Lachlan Smith (Chief Financial Officer) of RUA Life Sciences hosted an online presentation for investors. The team covered highlights of their Interim Results (to 30th September) and the successful fund raise announced after period end. Management discussed the shorterterm commercialisation opportunities present in RUA Structural Heart and RUA Contract Manufacture, and how the agreed regulatory pathway enables engagement with potential partners to facilitate the commercialisation of RUA Vascular. The team also answered a range of questions from viewers.

RUA Life Sciences (AIM: RUA) is the holding company of a group of medical device businesses focused on the exploitation of the world's leading longterm implantable biostable polymer (ElastEon™). Equity Development's research content on RUA can be found here: https://www.equitydevelopment.co.uk/r...

Timestamps
0:00:00 Beginning
0:00:11 Introduction to RUA Life Sciences
0:01:13 Financial overview (Interim Results)
0:06:01 Segmental analysis
0:07:03 Portfolio Businesses
0:08:34 What is ElastEon™?
0:11:17 Contract Manufacturing
0:14:25 Structural Heart
0:24:32 Vascular
0:29:06 Portfolio Management & Summary (including completed fund raise)
0:32:32 Questions & Answers